Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.
Big Pharma leaders presenting earnings this week largely shrugged off the potential of renewed risk ahead for drug pricing, with President Donald Trump’s Most Favored Nation initiative already embedded into assumptions.
Even with Democrats regaining control of Congress during Tuesday’s mid-term elections, executives were steadfast. Novo’s Mike Maziar Doustdar, reporting from Copenhagen Wednesday morning, was the first to speak to U.S. policy points after the blue wave.
“There’s always been a strong bipartisan support from both sides of the aisle for what we do,” Doustdar said. “We improve health at scale—whether you’re Republican or Democrat, you welcome that for your constituents.” He pledged to work closely with either party on “making sure that we can be a meaningful partner” to the U.S.
Leerink Partners warned that the Democrats could renew a push to lower drug prices but would likely have bigger issues to tackle first as they take control in Washington.
“Democrats likely have ‘bi...